Innoviva (NASDAQ:INVA) Stock Unloaded Rep. George Whitesides

Representative George Whitesides (D-California) recently sold shares of Innoviva, Inc. NASDAQ: INVA. In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $50,001 and $100,000 in Innoviva stock on March 24th. The trade occurred in the Representative's "GEORGE WHITESIDES INDIVIDUAL" account.

Representative George Whitesides also recently made the following trade(s):

• Sold $100,001 - $250,000 in shares of Netflix NASDAQ: NFLX on 3/27/2025.
• Sold $250,001 - $500,000 in shares of Innoviva NASDAQ: INVA on 3/25/2025.
• Sold $100,001 - $250,000 in shares of Linde NASDAQ: LIN on 3/24/2025.
• Sold $100,001 - $250,000 in shares of Procter & Gamble NYSE: PG on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Sandoz Group OTCMKTS: SDZNY on 3/24/2025.
• Sold $15,001 - $50,000 in shares of American Electric Power NASDAQ: AEP on 3/24/2025.
• Sold $50,001 - $100,000 in shares of Medtronic NYSE: MDT on 3/24/2025.
• Sold $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Bank of America NYSE: BAC on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Diageo NYSE: DEO on 3/24/2025.

Innoviva Trading Down 0.2 %

INVA traded down $0.04 during trading on Thursday, hitting $18.65. 522,577 shares of the stock were exchanged, compared to its average volume of 633,281. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. The firm has a 50 day simple moving average of $17.79 and a 200 day simple moving average of $18.38. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 27.03 and a beta of 0.48. Innoviva, Inc. has a 1 year low of $15.07 and a 1 year high of $21.28.

Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The firm had revenue of $91.81 million during the quarter. As a group, equities analysts expect that Innoviva, Inc. will post 0.33 EPS for the current year.

Insider Activity

In related news, major shareholder Alexander J. Denner sold 151,175 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.63, for a total value of $2,665,215.25. Following the completion of the transaction, the insider now directly owns 7,125,825 shares of the company's stock, valued at $125,628,294.75. This trade represents a 2.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.25% of the company's stock.

Hedge Funds Weigh In On Innoviva

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV boosted its holdings in shares of Innoviva by 73.9% in the 4th quarter. KBC Group NV now owns 4,100 shares of the biotechnology company's stock valued at $71,000 after buying an additional 1,743 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Innoviva by 75.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,962 shares of the biotechnology company's stock valued at $86,000 after acquiring an additional 2,128 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Innoviva by 10.3% in the first quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company's stock valued at $153,000 after acquiring an additional 795 shares in the last quarter. New Age Alpha Advisors LLC purchased a new position in Innoviva in the fourth quarter worth $176,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Innoviva during the fourth quarter worth $184,000. Hedge funds and other institutional investors own 99.12% of the company's stock.

Analysts Set New Price Targets

INVA has been the subject of several research reports. StockNews.com raised shares of Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday. Scotiabank started coverage on Innoviva in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company.

About Representative Whitesides

George Whitesides (Democratic Party) is a member of the U.S. House, representing California's 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Whitesides (Democratic Party) ran for election to the U.S. House to represent California's 27th Congressional District. He won in the general election on November 5, 2024. George Whitesides earned a bachelor's degree in public and international affairs from Princeton University in 1996 and a master's degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.